相关实验视频
Updated: Jul 16, 2026
06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
多模式融合与监督对比学习模型用于早期阿尔茨海默病诊断和多模式生物标志物识别
Xiaofeng Xie1, Peng Xue1, Yihao Guo2
1School of Mechanical and Electrical Engineering, Hainan University, Haikou, 570228, China.
Interdisciplinary sciences, computational life sciences
|February 3, 2026
概括
这项研究引入了一个新的框架来诊断阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 使用遗传,蛋白质和成像数据. 该方法具有很高的准确性,有助于早期发现和干预神经退行性疾病.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 生物标志物发现发现
背景情况:
- 轻度认知障碍 (MCI) 的早期诊断对于阿尔茨海默病 (AD) 的干预至关重要.
- 整合不同的数据类型,如遗传学,蛋白质学和神经成像,为准确的AD诊断带来了挑战.
研究的目的:
- 开发一个监督的对比学习框架,用于整合单核酸多态 (SNPs),等离子体蛋白质学和结构磁共振成像 (sMRI) 来诊断AD和MCI.
- 研究SNP,蛋白质表达和AD进展中的大脑结构改变之间的生物相互作用.
主要方法:
- 使用监督对比学习框架来整合多模式数据 (SNP,蛋白质组学,sMRI).
- 基于相似性的对称注意力机制被用来捕捉跨式交互并解决数据异质性.
- 该模型在阿尔茨海默病神经成像计划 (ADNI) 数据集上得到了验证.
主要成果:
- 拟议的方法实现了高诊断准确率:AD-NC为96.1%,MCI-NC为86.2%,AD-MCI为86.1%.
- 可解释的方法确定了对AD诊断至关重要的多模式生物标志物.
- 该框架在区分AD,MCI和健康对照方面表现出有效性.
结论:
- 开发的框架有效地整合了异质的多模式数据,用于准确的AD和MCI诊断.
- 这些发现强调了结合遗传,蛋白质和神经成像数据的潜力,以早期检测神经退行性疾病.
- 这项研究提供了一个强大的模型,用于识别生物标志物,并改善阿尔茨海默病及其前期阶段的诊断能力.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...